Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AN2 to go public to develop boron-containing drugs

by Michael McCoy
April 7, 2022 | A version of this story appeared in Volume 100, Issue 12

 

The structure of epetraborole.


AN2 Therapeutics is going public in an initial public stock offering that it hopes will raise $69 million. AN2 launched in 2019 to develop drug candidates including epetraborole, a boron-containing molecule discovered by Anacor Pharmaceuticals. Pfizer acquired Anacor in 2016 for about $5.2 billion, mainly for the eczema treatment crisaborole. Epetraborole is scheduled to begin Phase 2/3 clinical trials later this year as a treatment for a bacterial lung disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.